Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 9/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.68 |
| ▸ | TSHR | P16473 | 1/20 | 0.68 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.47 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.47 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3614598 | 1.00 | DNM1 (0.68) | DNM1ALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL8309033 | 1.00 | DNM1 (0.68) | DNM1ALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL22923343 | 1.00 | DNM1 (0.68) | DNM1ALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL21891269 | 1.00 | DNM1 (0.68) | DNM1ALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL24522348 | 1.00 | DNM1 (0.68) | DNM1ALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL22618484 | 1.00 | DNM1 (0.68) | DNM1ALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL24294234 | 1.00 | DNM1 (0.68) | DNM1ALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL21984825 | 1.00 | DNM1 (0.68) | DNM1ALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL22923237 | 1.00 | DNM1 (0.68) | DNM1ALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL9501455 | 1.00 | DNM1 (0.68) | DNM1ALDH1A1MEN1KMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023003922-A1 | METABOLIC DISORDER-ASSOCIATED TARGET GENE IRNA COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-01-26 | — | — | WO | disclosed |